Outlook on the Quit Smoking Drugs Market: Major Segments, Strategic Developments, and Leading Companies

The quit smoking drugs market is poised for impressive expansion in the coming years, driven by technological advancements and evolving healthcare practices. With increasing focus on personalized treatment and digital health integration, this sector is set to transform how smoking cessation therapies are delivered and managed globally.

Forecasted Growth and Size of the Quit Smoking Drugs Market
The quit smoking drugs market is predicted to grow at a rapid pace, reaching a value of $90.73 billion by 2030. This growth corresponds to a compound annual growth rate (CAGR) of 15.5%. Several factors contribute to this trend, including the rise of digital health solutions, the growing use of personalized medicine, the incorporation of artificial intelligence in treatment monitoring, expansion in telemedicine services, and the wider adoption of wearable health monitoring devices. Key trends expected to shape the market include personalized nicotine replacement therapies, the popularity of mobile health and smoking cessation apps, telemedicine-driven prescription support, the combining of behavioral therapy with drug treatments, and the use of wearable devices to track cravings.

Download a free sample of the quit smoking drugs market sample:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9247&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Leading Companies Operating in the Quit Smoking Drugs Market
The competitive landscape of the quit smoking drugs market features several prominent players such as 22nd Century Group, Cipla Limited, Dr. Reddy's Laboratories, GSK Plc., Johnson & Johnson, NJOY LLC, Perrigo Company Plc, Pfizer Inc., Philip Morris International, Glenmark Pharmaceuticals Limited, Zydus Cadila Healthcare Limited, BioCorRx Inc., Ennaid Therapeutics LLC, Fertin Pharma A/S, Hikma Pharmaceuticals PLC, IntelGenx Technologies Corp., Innovus Pharmaceuticals Inc., Gilla Inc., Rusan Pharma Ltd., and Novartis AG.

Notably, in September 2024, Dr. Reddy's Laboratories, an India-based pharmaceutical firm, acquired the nicotine replacement therapy portfolio from Haleon plc for $680 million (£500 million). This acquisition aims to bolster Dr. Reddy's global consumer healthcare presence by enhancing its over-the-counter (OTC) product range and expanding its footprint in key international markets beyond the United States. Haleon plc, headquartered in the UK, specializes in products addressing nicotine addiction.

View the full quit smoking drugs market report:
https://www.thebusinessresearchcompany.com/report/quit-smoking-drugs-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Emerging Trends Shaping the Quit Smoking Drugs Market
Top companies in this market are concentrating on developing innovative formulations and new methods of drug delivery, including generic tablets, to strengthen their leadership positions across different regions. The introduction of generic varenicline tablets-non-branded versions bioequivalent to the original branded product-is a key example. These tablets serve as a cost-effective option for smoking cessation therapy.

For instance, in January 2024, Lupin Limited from India launched generic Varenicline tablets in the United States. Available in 0.5 mg and 1 mg strengths, these tablets are generic alternatives to the branded Chantix (0.5 mg and 1 mg) from PF Prism C.V. Varenicline functions as a partial agonist of the nicotinic acetylcholine receptor, working by stimulating dopamine release to ease withdrawal symptoms and cravings. This dual action reduces the pleasurable effects of smoking while providing some stimulation to lessen withdrawal, making it an effective aid in quitting smoking.

Segment-Wise Overview of the Quit Smoking Drugs Market
This report divides the quit smoking drugs market into several key segments, which include:

1) Product Types: Drug Therapy, E-Cigarettes, Nicotine Inhalers, Nicotine Replacement Therapies, and Nicotine Sublingual Tablets.
2) Drug Categories: Varenicline (Chantix), Bupropion (Zyban), and Other Drugs.
3) Distribution Channels: Drug Stores, Online Pharmacies, and Retail Pharmacies.

Further subcategories for each segment include:
- Drug Therapy: Bupropion (Zyban) and Varenicline (Chantix).
- E-Cigarettes: Disposable E-Cigarettes, Rechargeable E-Cigarettes, and Pod Systems.
- Nicotine Inhalers: Prescription and Over-The-Counter Inhalers.
- Nicotine Replacement Therapies (NRT): Nicotine Patches, Nicotine Gum, and Nicotine Lozenges.
- Nicotine Sublingual Tablets: Fast-Acting and Extended-Release Sublingual Tablets.

This detailed segmentation provides a comprehensive understanding of the market's structure and the diverse range of products and channels contributing to its growth.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.